Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Effectiveness of Genotype-Specific Tricyclic Antidepressant Dosing in Patients With Major Depressive Disorder: A Randomized Clinical Trial.

JAMA network open - 1 May 2023

Vos Cornelis F, Ter Hark Sophie E, Schellekens Arnt F A, Spijker Jan, van der Meij Annemarie, Grotenhuis Anne J, Mihaescu Raluca, Kievit Wietske, Donders Rogier, Aarnoutse Rob E, Coenen Marieke J H, Janzing Joost G E

Abstract excerpt

Importance: Evidence of the clinical benefit of pharmacogenetics-informed treatment (PIT) with antidepressants is still limited. Especially for tricyclic antidepressants (TCAs), pharmacogenetics may be of interest because therapeutic plasma concentrations are well defined, identification of optimal dosing can be time consuming, and treatment is frequently accompanied by adverse effects. Objective: To determine...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antidepressive Agents
Share to Antidepressive Agents, Tricyclic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Depressive Disorder, Major

Share to Drug-Related Side Effects and Adverse Reactions

Share to Genotype

Source

Open in PubMed Open full text

Identifiers

PMID: 37155164
DOI: 10.1001/jamanetworkopen.2023.12443
PMCID: PMC10167565

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Effectiveness of Genotype-Specific Tricyclic Antidepressant Dosing in Patients With Major Depressive Disorder: A Randomized Clinical Trial.PMID 37155164Read ↗

Genotype-Specific Tricyclic Antidepressant Dosing in Patients With Major Depressive Disorder: A Trial-Based Economic Evaluation.Semantic proximity Read ↗

Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 updateSemantic proximity Read ↗

Genotype-Guided Antidepressant Prescribing for Patients With Depression: A Randomized Clinical Trial.Semantic proximity Read ↗

Optimizing Nortriptyline Dosing: A Comparison between Pharmacogenetics-Based, Phenotype-Based, and Standard Dosing.Semantic proximity Read ↗

Precision dosing for patients on tricyclic antidepressants.Semantic proximity Read ↗

Study protocol for an observational trial: Investigating pharmacogenetic impact on depression treatment using various sequencing and array methods (PharmGen-TRD Study)Semantic proximity Read ↗

Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants.Semantic proximity Read ↗

Using pharmacokinetics and pharmacogenetics to optimize psychiatric treatments: A systematic review.Semantic proximity Read ↗

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors.Semantic proximity Read ↗

Clinical application of antidepressant pharmacogenetics: Considerations for the design of future studiesSemantic proximity Read ↗

Pharmacogenetics testing for poor response to antidepressants: a transnosographic case seriesSemantic proximity Read ↗

Pharmacogenetics and the pharmacological management of depression.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.